based his "Expert Investor" opinion on Algernon Pharmaceuticals Phase 2a IPF and associated cough. What the "Expert Investor" did not mention is Algernon Pharmaceuticals did not reach statistical significance for chronic cough.
Andre Uddin - Algernon Pharmaceuticals only dedicated stock analyst and affiliate of Research Capital stated the following in this abbreviated and highlighted excerpt:
"According to the analyst, the IPF data achieved one of its primary endpoints as 13 (65%) of the 20 participants enrolled in the trial were shown to have had statistically significant improvement in FVC throughout the 12-week treatment period.
Research Capital mentioned that in the Phase 2 trial, ifenprodil did not meet its primary endpoint for the IPF with chronic cough part of the study…”
Drug Repurposing Co. Provides Opportunity for High Rewards
Full stop
Having stated that Algernon Pharmaceuticals will be entering a Phase 2 study for IPF/CC without strong supporting data for chronic cough. There is also no mention of timeline for the start and end of such clinical trials conducted in the abysmal patient recruitment environment of Australia.Thus, it remains anyone's guess if or when Algernon will seek the financing necessary to conduct such a clinical trial.
If the past is any indication of the future then I suspect Algernon will not start a Phase 2b clinical trial within a year from now if they're able to secure the necessary funds. It will likely be another capital raise the likes of the one being conducted now for 5M dollars or more. Your current ATM offering will double the outstanding shares. The pre|split shares are likely toast from hereafter. You will need overwhelming and massive returns to ever break even. Which falls in-line with a likely 4 years before Algernon Pharmaceuticals reaches a sata readout for IPF and cough in Australia ro receive a "Tax Rebate 5 years from now.
It all makes perfect sense/cents right?
Funny thing about Andre Uddins stock ratings is they're all over the map. Up Down Up... in such a short period of time. They seem to coincide with positive ratings when raising capital and negative ratings when the data flops. Three straight flops thus far:
1. COVID South Korea
2. COVID Romania which includes a serious hospital fire where 75% of patient records were being held.
3. Chronic Cough plus a 2 year timeline to reach data results for a 20 patient study. So that's really like two flops in one.
You can also throw in the 100 to 1 reverse split and colossal failure to uplist to NASDAQ. NASDAQ financing being the primary reason given by your CEO for the very harsh reverse split of shareholders. One would think, before committing to such a drastic and expensive move you would already have buyers lined up. So where was all the due diligence applied? You mean smart people at Algernon Pharmaceuticals didn't know which direction the US stock market was moving at the time, and chose to simply throw all caution to the wind?
Yeah, I get it loud and clear Algernon Pharmaceuticals. You Seek Safe Harbor.
Algernon Pharmaceuticals only analyst Uddin seems like an insiders|outside man whose coverage of Algernon Pharmaceuticals helps pay their corporate bills in the long run and primarily those bills immediately attached to his employers - Research Capital - bottom_line fees for service. This won't be the last time Algernon Pharmaceuticals gets slapped around by Smackie Mackie Research Capital (formerly known as Mackie Research Capital Corporation).
Everyone has an opinion and ^this is mine.